Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Cancer Discov. 2014 Nov 13;4(12):1377–1386. doi: 10.1158/2159-8290.CD-14-0477

Figure 2. Changes in the tumor microenvironment with BRAF inhibition.

Figure 2

Patients with metastatic melanoma treated with BRAF inhibitors were biopsied pre-treatment and 10-14 days after treatment initiation. BRAF inhibition is associated with an increase in CD8+ T cells, melanoma differentiation antigen expression, and the immunomodulatory molecule PD-L1. Adapted from Frederick et al., 2013 (12).